SCHEMBL1463012

SCHEMBL1463012

Nc1ccc(F)c(F)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21223626 0.78
SCHEMBL123657 0.74
SCHEMBL21722481 0.74
SCHEMBL2674520 0.74
SCHEMBL3059112 0.74
SCHEMBL91461 0.74
SCHEMBL18319850 0.74
SCHEMBL319387 0.74
SCHEMBL16992865 0.74
SCHEMBL15624392 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025125665-A1 FURTHER SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2025-06-19 WO disclosed
US-20250009742-A1 NOVEL CAPSID ASSEMBLY INHIBITORS META-IMMUNE, INC. (KR) 2025-01-09 US disclosed
EP-4416142-A1 NOVEL CAPSID ASSEMBLY INHIBITORS AM Sciences Inc (KR) 2024-08-21 EP disclosed
CN-118103363-A Novel capsid assembly inhibitor 南韩商AM科学股份有限公司 2024-05-28 CN disclosed
US-20230287005-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-09-14 US disclosed
US-20230287005-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-09-14 US disclosed
WO-2023063697-A1 NOVEL CAPSID ASSEMBLY INHIBITORS AM SCIENCES INC (KR) 2023-04-20 WO disclosed
EP-4121415-A1 INHIBITORS OF CYTOKININ OXIDASE DERIVED FROM 1-[2-(HYDROXYALKYL)PHENYL]-3-YLUREA, USE THEREOF AND PREPARATIONS CONTAINING THESE DERIVATIVES Univerzita Palackého v Olomouci (CZ) 2023-01-25 EP disclosed
CN-115551862-A Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2022-12-30 CN disclosed
WO-2021185391-A1 INHIBITORS OF CYTOKININ OXIDASE DERIVED FROM 1-[2-(HYDROXYALKYL)PHENYL]-3-YLUREA, USE THEREOF AND PREPARATIONS CONTAINING THESE DERIVATIVES UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2021-09-23 WO disclosed
US-10822352-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2020-11-03 US disclosed
CN-110483484-A Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug JANSSEN SCIENCES IRELAND UC 2019-11-22 CN disclosed
CN-105980378-B Sulfamoyl pyrrole amide derivative and application thereof as medicine for treating hepatitis B 爱尔兰詹森科学公司 2019-09-27 CN disclosed
CN-110121499-A (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides 优时比制药有限公司 2019-08-13 CN disclosed
US-20190211033-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2019-07-11 US disclosed
CN-105980378-A Sulfamoyl pyrrole amide derivative and application thereof as medicine for treating hepatitis B 爱尔兰詹森科学公司 2016-09-28 CN disclosed
EP-2473499-A1 BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-07-11 EP disclosed
CN-102471310-A Bipyridines useful for the treatment of proliferative diseases NOVARTIS AG 2012-05-23 CN disclosed
CN-102470127-A Biaryl compounds and methods of use thereof AMBIT BIOSCIENCES CORP 2012-05-23 CN disclosed
WO-2011026911-A1 BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2011-03-10 WO disclosed